Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
GLOBETECH PUBLISHING
Ampronix

Circulatory Support System Aids Failing Hearts

By HospiMedica International staff writers
Posted on 10 Jul 2013
Image: The Synergy Circulatory Support System (Photo courtesy of CircuLite).
Image: The Synergy Circulatory Support System (Photo courtesy of CircuLite).
A surgically implanted micropump aids ambulatory chronic heart failure (CHCF) patients who not respond to optimal medical treatment.

The Synergy Circulatory Support System is designed to reverse HF symptoms in ambulatory patients, promoting significant hemodynamic improvements, including decreased pulmonary artery and pulmonary capillary wedge pressures and increased cardiac output. The device provides up to 4.25 liters of blood per minute, reducing the heart's workload while improving blood flow to the final organs. The system is surgically implanted using a mini-thoracotomy procedure and the micro-pump is placed in a pacemaker-like pocket. The procedure is intended to reduce the surgical risks associated with cardiopulmonary bypass support platforms needed to place current ventricular assist devices (VADs).

The micropump combines axial, centrifugal, and orthogonal flow paths with a single-stage impeller that is powered by an integrated brushless microelectric motor; the entire system is the size of a standard AA battery. The design allows the motor to be sealed, thus eliminating blood contact in the motor, as well as a proprietary self-washing flow path and an alternating speed algorithm, both designed to minimize the risk of thrombus formation in or around the rotor. The Synergy Circulatory Support System is a product of CircuLite (Aachen, Germany) and has received the European Community CE marking of approval.

“The latest version of the Synergy System was shown to improve hemodynamics and functional status with comparably low adverse event rates in chronic ambulatory heart failure patients,” said Professor Bart Meyns, MD, PhD, chief of cardiac surgery at the University Hospitals Leuven (Belgium), who conducted the study in the final 26 patients of the clinical Synergy CE-Mark Trial. “The System has the potential for broad application in earlier-stage patients, who are not sick enough to justify the risks associated with more surgically-invasive assist devices.”

“The final modifications we made to the Synergy System have made a significant clinical difference, which was demonstrated in our clinical trial,” said Paul Southworth, CEO of CircuLite. “We showed positive outcomes and we have lowered adverse events in comparison to larger devices.”

Related Links:
CircuLite



Bovie Medical
MinXray
Centurion Service

Channels

Surgical Techniques

view channel
Image: The Optimis Fusion integrated laser platform (Photo courtesy of Quantel Medical).

Combination Laser Platform Treats Glaucoma and Cataract

An integrated laser offers ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform. The Optimis Fusion integrated laser combines advanced... Read more

Women's Health

view channel
Image: A prototype contraceptive implant (Photo courtesy of MicroCHIPS).

Contraceptive Implant Hails New Era of Birth Control

A fingernail-sized implant holds enough 30-microgram daily doses of levonorgestrel to provide contraception for 16 years. Developed by MicroCHIPS (Lexington, MA, USA), a MIT (Cambridge, MA, USA) startup,... Read more

Health IT

view channel

Wikipedia Dominates Internet Drug Information

Wikipedia, along with Google and WebMD, is where more than half of all Americans turn to for health information on prescription drugs. Researchers at the Blackstone Group (London, United Kingdom), Harvard Medical School (Boston, MA, USA), and other institutions selected new drug-safety communications related to prescription... Read more

Business

view channel

Spectranetics Completes Acquisition of AngioScore

Spectranetics (Colorado Springs, CO, USA) has completed the acquisition of AngioScore (Fremont, CA, USA), a leading developer, manufacturer, and marketer of cardiovascular specialty balloons. The transaction, for USD 230 million in cash and contingent commercial and regulatory milestone payments, will combine differentiated,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.